Open AccessAnti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
Author(s) -
Taichi Matsubara,
Takashi Seto,
Shinkichi Takamori,
Takatoshi Fujishita,
Ryo Toyozawa,
Kensaku Ito,
Masafumi Yamaguchi,
Tatsuro Okamoto
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s301500
Subject(s) - medicine , pembrolizumab , nivolumab , lung cancer , adverse effect , performance status , cohort , oncology , cancer , immunotherapy
Anti-programmed death 1 (PD-1) antibodies have emerged as frontline treatments for patients with advanced non-small cell lung cancer (NSCLC) on the basis of global Phase III trials. However, current data regarding responses to anti-PD-1 therapy in older patients with NSCLC or those with poor performance status (PS) are limited. Therefore, we examined the therapeutic effect of anti PD-1 antibody in these patients.